Breakthrough therapeutics for addiction

41M Americans with addictive disorders remain untreated due to the low efficacy and appeal of existing therapies.

No other class of indications has a larger unmet need.

⌜

⌝

⌞

⌟

Lead Asset

BT-001

Baseline's class-leading GLP-1RA weekly injectable for alcohol use disorder (AUD) and substance use disorder indications.

Outstanding safety across thousands of patients in metabolic trials.

Phase 3 trials for AUD launching in 2026, with additional indications to follow.